1.Study on the epidemiology and HCV genotype distribution of HIV/HCV co-infection among HIV infected blood donors in China.
Zhen LIU ; Wen-ge XING ; Yong-hong ZHANG ; Qi ZHANG ; Xiao-shan LONG ; Gui-yun ZHANG ; Hao WU ; Yan JIANG
Chinese Journal of Hepatology 2006;14(6):464-465
Adult
;
Blood Donors
;
China
;
epidemiology
;
Female
;
Genotype
;
HIV Infections
;
complications
;
epidemiology
;
virology
;
Hepacivirus
;
genetics
;
Hepatitis C
;
complications
;
epidemiology
;
virology
;
Humans
;
Male
;
Middle Aged
2.Human Papillomavirus Prevalence and Genotype Distribution among HIV-Infected Women in Korea.
Eun Kyoung PARK ; Heerim CHO ; Sun Hee LEE ; Seung Geun LEE ; Sang Yeup LEE ; Ki Hyung KIM ; Chang Hun LEE ; Joo Seop CHUNG ; Ihm Soo KWAK
Journal of Korean Medical Science 2014;29(1):32-37
The epidemiology on human papillomavirus (HPV) among human immunodeficiency virus (HIV)-infected women in Korea is not well established. A retrospective study was conducted to determine the prevalence and genotype distribution of HPV infection among HIV-infected women in Korea. HPV DNA genotype and cervical cytology were examined in 60 HIV-positive women and 1,938 HIV-negative women. HPV genotypes were analyzed by using a HPV DNA chip. HIV-infected women had higher prevalence of high-risk HPV (hr-HPV) infection (30% vs 4.9%, adjusted odds ratio [AOR], 6.96; 95% confidence interval [CI], 3.63-13.34, P<0.001) and abnormal cervical cytology (18.3% vs 1.8%, AOR, 10.94; 95% CI, 5.18-23.1, P<0.001) compared with controls. The most common hr-HPV genotype detected in HIV-infected women was HPV 16 (10%), followed by 18 (6.7%) and 52 (5%). Prevalence of quadrivalent vaccine-preventable types (HPV 6, 11, 16, and 18) was 21.7% and 2.3% in HIV-positive women and HIV-negative women, respectively. Age was a significant risk factor for hr-HPV infection in HIV-infected women (P=0.039). The presence of hr-HPV was significantly associated with abnormal cervical cytology (P<0.001). These findings suggest that HPV testing for cervical cancer screening in HIV-infected women would be necessary, particularly among young age group.
Adult
;
Age Factors
;
Cervix Uteri/virology
;
DNA Probes, HPV/diagnostic use
;
DNA, Viral/genetics
;
Female
;
Genotype
;
HIV Infections/complications/*epidemiology/genetics
;
HIV-1/genetics
;
Human papillomavirus 11/genetics/isolation & purification
;
Human papillomavirus 16/genetics/isolation & purification
;
Human papillomavirus 18/genetics/isolation & purification
;
Human papillomavirus 6/genetics/isolation & purification
;
Humans
;
Middle Aged
;
Papillomavirus Infections/complications/*epidemiology/*genetics
;
Prevalence
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Risk Factors
;
Uterine Cervical Neoplasms/epidemiology/genetics/virology
3.Incidence of Atazanavir-associated Hyperbilirubinemia in Korean HIV Patients: 30 Months Follow-up Results in a Population with Low UDP-glucuronosyltransferase1A1*28 Allele Frequency.
Pyoeng Gyun CHOE ; Wan Beom PARK ; Jin Su SONG ; Nak Hyun KIM ; Kyoung Ho SONG ; Sang Won PARK ; Hong Bin KIM ; Nam Joong KIM ; Myoung Don OH
Journal of Korean Medical Science 2010;25(10):1427-1430
Hyperbilirubinemia is frequently observed in Caucasian HIV patients treated with atazanavir. UDP-glucuronosyltransferase 1A1 polymorphism, UGT1A1*28, which is associated with atazanavir-induced hyperbilirubinemia, is less common in Asians than in Caucasians. However, little is known about the incidence of atazanavir-associated hyperbilirubinemia in Asian populations. Our objective was to investigate the incidence of and tolerability of atazanavir-associated hyperbilirubinemia in Korean HIV patients. The prevalence and cumulative incidence of atazanavir-associated hyperbilirubinemia and UGT1A1*28 allele frequency was investigated in 190 Korean HIV-infected patients treated with atazanavir 400 mg per day. The UGT1A1*28 were examined by direct sequencing of DNA from peripheral whole blood. The UGT1A1*28 allele frequency was 11%. The cumulative incidence of any grade of hyperbilirubinemia was 77%, 89%, 98%, and 100%, at 3, 12, 24, and 30 months, respectively. The cumulative incidence of severe (grade 3-4) hyperbilirubinemia was 21%, 41%, 66%, and 75%, at 3, 12, 24, and 30 months, respectively. However, the point prevalence of severe hyperbilirubinemia did not increase with time and remained around 25%. Our data suggest that atazanavir-associated hyperbilirubinemia is common but transient in a population with low UGT1A1*28 allele frequency.
Adult
;
Alleles
;
Anti-HIV Agents/*adverse effects/therapeutic use
;
Asian Continental Ancestry Group/*genetics
;
Female
;
Follow-Up Studies
;
Gene Frequency
;
Glucuronosyltransferase/blood/*genetics
;
HIV Infections/complications/*drug therapy
;
Humans
;
Hyperbilirubinemia/complications/*epidemiology/genetics
;
Incidence
;
Male
;
Middle Aged
;
Oligopeptides/*adverse effects/therapeutic use
;
Promoter Regions, Genetic
;
Pyridines/*adverse effects/therapeutic use
;
Republic of Korea